SCHEMBL4680684

SCHEMBL4680684

COc1ccc(CSC(=O)N2CCNCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
KDM1A O60341 1/20 0.50
HSD17B10 Q99714 1/20 0.48
MAPT P10636 2/20 0.48
IDO1 P14902 2/20 0.48
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
ADRB1 P08588 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
TMEM97 Q5BJF2 1/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42
FKBP1A P62942 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4684148 0.99 SMN1; SMN2 (0.51) SMN1; SMN2KDM1AHSD17B10MAPTIDO1
SCHEMBL4680022 0.88 SMN1; SMN2 (0.47) SMN1; SMN2KDM1AMAPTALDH1A1GAA
SCHEMBL4684855 0.88 ALDH1A1 (0.48) SMN1; SMN2KDM1AHSD17B10ALDH1A1PKM
Hydrochloric Acid SCHEMBL4684420 0.87 SMN1; SMN2 (0.46) SMN1; SMN2KDM1AMAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL4684401 0.87 ALDH1A1 (0.47) SMN1; SMN2KDM1AHSD17B10IDO1ALDH1A1
SCHEMBL11715776 0.86 HPGD (0.53) SMN1; SMN2MAPTIDO1ALDH1A1POLB
SCHEMBL4679259 0.84 IDO1 (0.42) KDM1AIDO1SIGMAR1POLB
SCHEMBL4682060 0.83 HRH3 (0.46) ALDH1A1
Hydrochloric Acid SCHEMBL4678909 0.82 HRH3 (0.46) ALDH1A1
SCHEMBL4681022 0.81 TPSAB1 (0.39) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 SMN1; SMN2 1517/4885KDM1A 521/4885HSD17B10 1745/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 SMN1; SMN2 1517/4885KDM1A 521/4885HSD17B10 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.